insulin rohit bharti
TRANSCRIPT
![Page 1: Insulin rohit bharti](https://reader030.vdocuments.mx/reader030/viewer/2022032616/55a4fc011a28ab602e8b4657/html5/thumbnails/1.jpg)
![Page 2: Insulin rohit bharti](https://reader030.vdocuments.mx/reader030/viewer/2022032616/55a4fc011a28ab602e8b4657/html5/thumbnails/2.jpg)
ILO’S
1. Introduction
2. Synthesis & Metabolism
3. Insulin secretion
4. Physiological roles
5. Insulin effects
6. Deficiency of insulin
7. Symptoms
8. Excess of Insulin
9. Oral Hypoglycaemic Agents
10.Synthesis
![Page 3: Insulin rohit bharti](https://reader030.vdocuments.mx/reader030/viewer/2022032616/55a4fc011a28ab602e8b4657/html5/thumbnails/3.jpg)
It was first isolated in 1921 by Banting and Best and therapeutically used in 1922.
Human insulin now been produced from E-coli by recombinant DNA technology.
![Page 4: Insulin rohit bharti](https://reader030.vdocuments.mx/reader030/viewer/2022032616/55a4fc011a28ab602e8b4657/html5/thumbnails/4.jpg)
![Page 5: Insulin rohit bharti](https://reader030.vdocuments.mx/reader030/viewer/2022032616/55a4fc011a28ab602e8b4657/html5/thumbnails/5.jpg)
![Page 6: Insulin rohit bharti](https://reader030.vdocuments.mx/reader030/viewer/2022032616/55a4fc011a28ab602e8b4657/html5/thumbnails/6.jpg)
(1) Proinsulin is the immediate precursor to insulin in the single-chain peptide.
(2) Proinsulin folds to adopt the ‘correct orientation of the prevailing ‘disulphide bonds’ plus other relevant conformational constraints whatsoever on account of its primary structure exclusively.
(3) Proinsulin in reality, has a precursor of its own, preproinsulin–a peptide, that essentially comprises of hundreds of ‘additional residues’.
(4) At an emerging critical situation the insulin gets generated from proinsulin due to the ensuing cleavage of proinsulin at the two points indicated.
This eventually produces insulin.
![Page 7: Insulin rohit bharti](https://reader030.vdocuments.mx/reader030/viewer/2022032616/55a4fc011a28ab602e8b4657/html5/thumbnails/7.jpg)
![Page 8: Insulin rohit bharti](https://reader030.vdocuments.mx/reader030/viewer/2022032616/55a4fc011a28ab602e8b4657/html5/thumbnails/8.jpg)
![Page 9: Insulin rohit bharti](https://reader030.vdocuments.mx/reader030/viewer/2022032616/55a4fc011a28ab602e8b4657/html5/thumbnails/9.jpg)
![Page 10: Insulin rohit bharti](https://reader030.vdocuments.mx/reader030/viewer/2022032616/55a4fc011a28ab602e8b4657/html5/thumbnails/10.jpg)
![Page 11: Insulin rohit bharti](https://reader030.vdocuments.mx/reader030/viewer/2022032616/55a4fc011a28ab602e8b4657/html5/thumbnails/11.jpg)
![Page 12: Insulin rohit bharti](https://reader030.vdocuments.mx/reader030/viewer/2022032616/55a4fc011a28ab602e8b4657/html5/thumbnails/12.jpg)
![Page 13: Insulin rohit bharti](https://reader030.vdocuments.mx/reader030/viewer/2022032616/55a4fc011a28ab602e8b4657/html5/thumbnails/13.jpg)
![Page 14: Insulin rohit bharti](https://reader030.vdocuments.mx/reader030/viewer/2022032616/55a4fc011a28ab602e8b4657/html5/thumbnails/14.jpg)
![Page 15: Insulin rohit bharti](https://reader030.vdocuments.mx/reader030/viewer/2022032616/55a4fc011a28ab602e8b4657/html5/thumbnails/15.jpg)
Normal blood glucose level: 70-90 mg/100ml
![Page 16: Insulin rohit bharti](https://reader030.vdocuments.mx/reader030/viewer/2022032616/55a4fc011a28ab602e8b4657/html5/thumbnails/16.jpg)
![Page 17: Insulin rohit bharti](https://reader030.vdocuments.mx/reader030/viewer/2022032616/55a4fc011a28ab602e8b4657/html5/thumbnails/17.jpg)
![Page 18: Insulin rohit bharti](https://reader030.vdocuments.mx/reader030/viewer/2022032616/55a4fc011a28ab602e8b4657/html5/thumbnails/18.jpg)
![Page 19: Insulin rohit bharti](https://reader030.vdocuments.mx/reader030/viewer/2022032616/55a4fc011a28ab602e8b4657/html5/thumbnails/19.jpg)
![Page 20: Insulin rohit bharti](https://reader030.vdocuments.mx/reader030/viewer/2022032616/55a4fc011a28ab602e8b4657/html5/thumbnails/20.jpg)
CLASSIFICATION OF ORAL HYPOGLYCEMIC AGENTS
(i)Sulfonylureas:
First-Generation Sulfonylureas: Acetohexamide ; Chlorpropamide ; Tolazamide
Second-Generation Sulfonylureas: Glipizide ; Glyburide ; Glumepiride
(ii) Non sulfonylureas: repaglinide, nateglinide
(iii) Thiazolindiones: Rosiglitazone, Troglitazone
(iv) Bisguanides: metoformin, phenoformin
(v) α-Glucosidase Inhibitors: Acarbose
![Page 21: Insulin rohit bharti](https://reader030.vdocuments.mx/reader030/viewer/2022032616/55a4fc011a28ab602e8b4657/html5/thumbnails/21.jpg)
Sulfonylureas
(1) These are urea derivatives having an arylsulfonyl moiety in the 1 position and an aliphatic function at the 3-position.
(2) The aliphatic moiety, R′, essentially confers lipophilic characteristic properties to the newer drug molecule.
(3) Optimal therapeutic activity often results when R′ comprises of 3 to 6 carbon atoms, as in acetohexamide, chlorpropamide and tolbutamide.
(4) Aryl functional moieties at R′ invariably give rise to toxic compounds.
(5) The R moiety strategically positioned on the ‘aromatic ring’ is primarily responsible forthe duration of action of the compound.
SAR :
![Page 22: Insulin rohit bharti](https://reader030.vdocuments.mx/reader030/viewer/2022032616/55a4fc011a28ab602e8b4657/html5/thumbnails/22.jpg)
![Page 23: Insulin rohit bharti](https://reader030.vdocuments.mx/reader030/viewer/2022032616/55a4fc011a28ab602e8b4657/html5/thumbnails/23.jpg)
![Page 24: Insulin rohit bharti](https://reader030.vdocuments.mx/reader030/viewer/2022032616/55a4fc011a28ab602e8b4657/html5/thumbnails/24.jpg)
![Page 25: Insulin rohit bharti](https://reader030.vdocuments.mx/reader030/viewer/2022032616/55a4fc011a28ab602e8b4657/html5/thumbnails/25.jpg)
![Page 26: Insulin rohit bharti](https://reader030.vdocuments.mx/reader030/viewer/2022032616/55a4fc011a28ab602e8b4657/html5/thumbnails/26.jpg)